A liquid chromatography packing material which includes a polymer packing material into which 1.50 mmol or more of carboxyl groups are introduced per 1 g of the packing material, and an index indicating pH of the surface of the polymer packing material as determined by hydrophilic interaction chromatography (HILIC) is 1.30 or more and the index indicating hydrophilicity of the surface of the polymer packing material as determined by a hydrophilic interaction chromatography (HILIC) is from 1.00 to 1.30.

The present invention provides novel chromatographic materials, e.g., for chromatographic separations, processes for its preparation and separations devices containing the chromatographic material; separations devices, chromatographic columns and kits comprising the same; and methods for the preparation thereof. The chromatographic materials of the invention are high purity chromatographic materials comprising a chromatographic surface wherein the chromatographic surface comprises a hydrophobic surface group and one or more ionizable modifier.

Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.

The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant by overloading a chromatography material and eluting the product.

The present invention provides a functionalised polymeric chromatography medium, prepared by a process which comprises (i) providing a substrate formed of one or more polymer nanofibres, (ii) grafting one or more neutral polymer chains from the substrate, and (iii) contacting the grafted product with a reagent which functionalises the product of step (ii) as a chromatography medium, wherein step (ii) comprises reacting a plurality of compounds of formula and/or its enantiomers, and/or its derivatives of formula (I) and/or enantiomers and/or diastereomers thereof: with one or more functional groups present on the nanofibre substrate, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 may be the same or different, and are chosen from H, halogen, C.sub.1-C.sub.4 alkyl, or C.sub.1-C.sub.4 alkoxy provided that at least one of R.sub.1, R.sub.2, R.sub.3, R.sub.4 or R.sub.5 is not hydrogen. ##STR00001##

Methods and kits for purifying protein-nanoparticle conjugates are provided. In some embodiments, a multimodal medium having a size exclusion mode and a capture mode is used to purify the protein-nanoparticle conjugates.

Solutions, detection methods and chromatographic systems are provided for electrospray ionization of glycans modified with amphipathic, strongly basic moieties. The solutions for use in electrospray ionization comprise a plurality of glycans having an amphipathic moiety, a basic residue of pKa>5 and a Log P value between 1 and 3, and one or more volatile components selected from the group consisting of an amine, ammonia, ammonia salt, diethylamine, or trimethylamine. The solutions also have a pH between about 3 to about 6, and ionic strength of between about 0 mM to about 500 mM. The solutions are useful in detecting modified glycans in electrospray ionization and in various chromatographic systems.

Described are methods for producing recombinant Arginase, such as PEGylated, cobalt-substituted recombinant human Arginase 1. Also described are pharmaceutical compositions comprising such recombinant Arginase, as well as methods of treatment and uses of such recombinant Arginase.

Described are methods for producing recombinant Arginase, such as PEGylated, cobalt-substituted recombinant human Arginase 1. Also described are pharmaceutical compositions comprising such recombinant Arginase, as well as methods of treatment and uses of such recombinant Arginase.

The present invention relates to a method to improve chromatography beads. More closely, the invention relates to a novel method for production of dextran-containing porous media and chromatography media produced with this method. In the method, the chromatography media is subjected to dextranase-treatment leading to improved pressure-flow properties of the media.